Joseph Drabick

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type

M. Oberley, P. Stafford, E. Heath, 2021, Translational oncology.

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

D. Munn, R. McWilliams, R. Kolhe, 2021, Journal for ImmunoTherapy of Cancer.

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

M. Kaag, V. Walter, Y. Zakharia, 2023, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .